- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07826650
The Impact of Acute Pain on Sleep Parameters in the Insomnia Population and Healthy Controls
The Impact of Acute Pain on Sleep Parameters in the Insomnia Population and Healthy Controls: a Case-control Study
This study investigates how acute exercise-induced muscular pain affects sleep quality and sleep architecture in people with insomnia compared to healthy sleepers.
Sleep disturbances and pain often influence each other, creating a negative cycle; however, it remains unclear how acute muscle pain-such as delayed-onset muscle soreness (DOMS) after strenuous exercise-alters continuous sleep parameters and pain sensitivity differently in clinical insomnia populations versus healthy controls.
Participants will be divided into two groups: individuals with clinical insomnia and age- and sex-matched healthy sleepers. Both groups will undergo a standardised exercise protocol designed to safely induce temporary, acute muscular soreness (DOMS). Objective sleep parameters (measured via wrist actigraphy) and subjective sleep parameters (measured via sleep diaries), will be monitored before and after the pain induction. The primary goal is to determine whether individuals with insomnia experience greater sleep disruption and altered pain recovery trajectories following an acute painful event compared to healthy individuals.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Leo Guohui Lin
- Numero di telefono: +852 94267004
- Email: guohui-leo.lin@connect.polyu.hk
Luoghi di studio
-
-
-
Hong Kong, Hong Kong
- Reclutamento
- The Hong Kong Polytechnic University
-
Contatto:
- Leo Guohui Lin
- Numero di telefono: +852 94267004
- Email: guohui-leo.lin@connect.polyu.hk
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Adults aged 18 to 60 years
- Right-hand and right-foot dominant
Exclusion Criteria:
- History of any chronic musculoskeletal pain or presence of existing pain during recruitment
- Previous major injuries or surgery involving the lower limbs
- Sleep disorders other than insomnia
- Clinically diagnosed psychiatric disorders
- Contraindications to vigorous exercise identified through the physical activity readiness questionnaire (PAR-Q)
- Work night shifts or rotating shift schedules
- Pregnant
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Insomnia
|
Eccentric hamstring exercise
|
|
Healthy contry
|
Eccentric hamstring exercise
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Sleep diary: Total Sleep Time
Lasso di tempo: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Total Sleep Time is calculated as the total time spent asleep, derived from the total time in bed (bedtime to wake time) minus sleep onset latency and wake after sleep onset.
Higher values indicate longer sleep duration.
|
Day 0 to Day 14
|
|
Sleep diary: Sleep Onset Latency (SOL)
Lasso di tempo: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Sleep Onset Latency is the estimated time (in minutes) it takes to fall asleep after turning off the lights.
Lower values indicate better sleep onset.
|
Day 0 to Day 14
|
|
Sleep diary: Wake After Sleep Onset (WASO)
Lasso di tempo: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
WASO is calculated as the total duration of wakefulness (in minutes) between initial sleep onset and final awakening, derived from the number of night awakenings multiplied by their average duration.
Lower values indicate better sleep continuity.
|
Day 0 to Day 14
|
|
Sleep diary: Sleep Efficiency (SE)
Lasso di tempo: Day 0 to Day 14
|
Assessed using a daily consensus sleep diary.
Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100].
Total Sleep Time is derived from total time in bed (time between bedtime and rise time) minus sleep onset latency and nocturnal wakefulness (calculated from the number and duration of night awakenings).
Scores range from 0% to 100%, with higher percentages indicating better sleep quality.
|
Day 0 to Day 14
|
|
Actigraphy: Total Sleep Time (TST)
Lasso di tempo: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer and validated sleep-scoring algorithms.
Total Sleep Time is defined as the total amount of time spent sleeping between bedtime and rise time.
Higher values indicate longer sleep duration.
|
Day 0 to Day 14
|
|
Actigraphy: Sleep Onset Latency (SOL)
Lasso di tempo: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
Sleep Onset Latency is the time (in minutes) between the initial bedtime (lights out) and the onset of continuous sleep detected by the algorithm.
Lower values indicate faster sleep onset and better sleep initiation.
|
Day 0 to Day 14
|
|
Actigraphy: Wake After Sleep Onset (WASO)
Lasso di tempo: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
WASO is defined as the total number of minutes spent awake after initial sleep onset and before final awakening, as determined by epoch-by-epoch movement counts.
Lower values indicate better sleep continuity and fewer night awakenings.
|
Day 0 to Day 14
|
|
Actigraphy: Sleep Efficiency (SE)
Lasso di tempo: Day 0 to Day 14
|
Measured objectively using a wrist-worn ActiGraph accelerometer.
Sleep Efficiency is calculated as the percentage of time in bed spent asleep: [(Total Sleep Time / Total Time in Bed) × 100].
Values range from 0% to 100%, with higher percentages indicating better sleep quality and efficiency.
|
Day 0 to Day 14
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Muscle damage severity: Muscle pain
Lasso di tempo: Day 0 to Day 14
|
Muscle pain will be measured by an 11-point NRS, with 0 represents "no pain" and 10 indicating "worst imaginable pain".
The Outcome will be recorded at rest, reach for the floor with knees straight, and during a validated hamstring provocative manoeuvre, the "taking-off shoe" test.
|
Day 0 to Day 14
|
|
Muscle damage severity: Muscle soreness
Lasso di tempo: Day 0 to Day 14
|
Muscle soreness will be measured by an 7-point Likert scale, with 0= A complete absence of soreness," 1 = "A light soreness in the muscle felt only when touched/a vague ache," 2 = "A moderate soreness felt only when touched/a slight persistent pain," 3 = "A light muscle soreness when walking up and down stairs," 4 = "A light muscle soreness when walking on flat surface," 5 = "A moderate muscle soreness, stiffness, or weakness when walking," 6 = "A severe muscle soreness, stiffness, or weakness that limits my ability to move."
|
Day 0 to Day 14
|
|
Sleep Questionnaires: the Insomnia Severity Index (ISI)
Lasso di tempo: Day 0 and Day 7
|
The ISI is a 7-item self-report questionnaire assessing the nature, severity, and impact of insomnia.
Each item is rated on a 5-point Likert scale (0 to 4).
The total score ranges from 0 to 28, with higher scores indicating greater severity of insomnia
|
Day 0 and Day 7
|
|
Sleep Questionnaires: The Pittsburgh Sleep Quality Index (PSQI)
Lasso di tempo: Day 0 and Day 7
|
The PSQI is a 19-item self-report questionnaire that evaluates sleep quality and disturbances over a 1-month time interval.
It generates seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction.
Each component is scored from 0 to 3. The sum of these seven component scores yields a global PSQI score ranging from 0 to 21, where higher scores indicate poorer sleep quality.
|
Day 0 and Day 7
|
|
Psychological measurement: Depression, Anxiety, and Stress Scale (DASS-21)
Lasso di tempo: Day 0, Day 7, and Day 9
|
Assessed using the 21-item Depression Anxiety Stress Scales (DASS-21).
The instrument consists of three 7-item subscales measuring depression, anxiety, and stress.
Each item is rated on a 4-point Likert scale ranging from 0 ("did not apply to me at all") to 3 ("applied to me very much or most of the time").
Sum scores for each subscale are calculated and multiplied by 2 to yield total scores ranging from 0 to 42 for each dimension (Depression: 0-42, Anxiety: 0-42, Stress: 0-42), with a total overall score ranging from 0 to 126.
Higher scores indicate greater levels of psychological distress/severity.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Pain Catastrophizing Scale (PCS)
Lasso di tempo: Day 0, Day 7, and Day 9
|
Assessed using the 13-item Pain Catastrophizing Scale (PCS) to evaluate catastrophic thoughts and feelings associated with pain (comprising rumination, magnification, and helplessness subscales).
Each item is rated on a 5-point Likert scale from 0 ("not at all") to 4 ("all the time").
The total score ranges from 0 to 52, with higher scores indicating higher levels of pain catastrophizing.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Fear of Pain Questionnaire (FPQ-9)
Lasso di tempo: Day 0, Day 7, and Day 9
|
Assessed using the 9-item short form of the Fear of Pain Questionnaire (FPQ-9) to assess fear of different painful experiences across severe pain, minor pain, and medical pain domains.
Each item is rated on a 5-point Likert scale from 1 ("not at all") to 5 ("extreme").
The total score ranges from 9 to 45, with higher scores indicating greater fear of pain.
|
Day 0, Day 7, and Day 9
|
|
Psychological measurement: Tampa Scale for Kinesiophobia (TSK-11)
Lasso di tempo: Day 0, Day 7, and Day 9
|
Assessed using the 11-item Tampa Scale for Kinesiophobia (TSK-11) to evaluate fear of movement or (re)injury.
Each item is scored on a 4-point Likert scale ranging from 1 ("strongly disagree") to 4 ("strongly agree").
The total score ranges from 11 to 44, with higher scores indicating greater fear of movement/kinesiophobia.
|
Day 0, Day 7, and Day 9
|
|
Physical Activity Level: International Physical Activity Questionnaire - Short Form (IPAQ-SF)
Lasso di tempo: Day 0 and Day 7
|
Assessed using the 7-item International Physical Activity Questionnaire - Short Form (IPAQ-SF).
The questionnaire measures the duration (minutes) and frequency (days) of walking, moderate-intensity activities, and vigorous-intensity activities performed over the last 7 days.
Total physical activity volume is calculated as MET-minutes per week (MET-min/week) using standardised MET energy expenditure values: Walking = 3.3 METs, Moderate PA = 4.0 METs, and Vigorous PA = 8.0 METs.
Total score is the sum of (METs × minutes × days) across all three domains, starting at 0 with no strict upper limit.
Higher scores indicate higher levels of overall physical activity.
|
Day 0 and Day 7
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Dolore
- Manifestazioni neurologiche
- Malattie muscoloscheletriche
- Malattie del sistema nervoso
- Malattie muscolari
- Disordini mentali
- Disturbi del sonno e della veglia
- Disturbi del sonno, intrinseci
- Dissonnie
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Dolore muscoloscheletrico
- Disturbi dell'inizio e del mantenimento del sonno
Altri numeri di identificazione dello studio
- Pain-Sleep-2026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .